New combo therapy may prevent bone loss after stopping osteoporosis drug
NCT ID NCT07281586
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 26 times
Summary
This study looks at a new way to stop taking the osteoporosis drug denosumab (Prolia) without losing bone density. When people stop denosumab after using it for years, their bones can weaken quickly. The standard approach of switching to another drug often doesn't fully prevent this. The trial tests a step-down plan: using a half-dose of denosumab along with another bone-strengthening drug (zoledronic acid) to see if it better protects the spine. About 44 postmenopausal women and men aged 50–85 who have taken denosumab for at least 3 years will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital Yunlin Branch
RECRUITINGDouliu, Taiwan, 640, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.